The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Circulating tumor DNA (ctDNA) as a marker of residual disease and recurrence in resected stage I-IV epithelial ovarian cancer (EOC).
 
Sumitra Ananda
No Relationships to Disclose
 
Yuxuan Wang
No Relationships to Disclose
 
Wei Hong
No Relationships to Disclose
 
Gary Edward Richardson
Research Funding - Adagene (Inst); Agenus (Inst); AstraZeneca (Inst); BeiGene (Inst); Bio-Thera Solutions (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CBT Pharmaceuticals (Inst); ChemoCentryx (Inst); Corvus Pharmaceuticals (Inst); Curon Biopharmaceutical (Inst); D3 Bio (Inst); Eucure Biopharma (Inst); Five Prime Therapeutics (Inst); Fosun Pharma (Inst); Gene Quantum (Inst); Genfleet Therapeutics (Inst); ImmunGen Inc (Inst); Imugene (Inst); InventisBio (Inst); Janssen Oncology (Inst); Keythera Pharmaceuticals (Inst); LaNova Australia (Inst); Medicenna (Inst); Merck (Inst); Minghui Pharmaceutical (Inst); Neoleukin Therapeutics (Inst); Novotech (Inst); Pfizer (Inst); PharmAbcine (Inst); RemeGen (Inst); Roche/Genentech (Inst); Seagen (Inst); Senz Oncology (Inst); Shanghai Henlius Biotech (Inst); Shanghai Henlius Biotech (Inst); Surface Oncology (Inst); Suzhou Alphamab (Inst); Takeda (Inst); Therapim (Inst); Zentalis (Inst)
 
Janine Margaret Lombard
Honoraria - AstraZeneca; GlaxoSmithKline; Novartis
Consulting or Advisory Role - AstraZeneca
Travel, Accommodations, Expenses - Lilly
 
Geraldine Goss
No Relationships to Disclose
 
Linda R. Mileshkin
Research Funding - BeiGene (Inst)
 
Christopher B. Steer
Honoraria - AstraZeneca; Eisai; MSD Oncology; Mundipharma; Novartis; Roche
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Ipsen; Janssen; MSD; Sanofi
Expert Testimony - Janssen
Travel, Accommodations, Expenses - Janssen
 
Anne Marie Lennon
No Relationships to Disclose
 
Orla McNally
No Relationships to Disclose
 
Christopher B Douville
No Relationships to Disclose
 
Maria Popoli
No Relationships to Disclose
 
Janine Ptak
No Relationships to Disclose
 
Natalie Silliman
No Relationships to Disclose
 
Lisa Dobbyn
No Relationships to Disclose
 
Nickolas Papadopoulos
Leadership - NeoPhore; Thrive Earlier Detection Corp
Stock and Other Ownership Interests - Cage Pharma; Haystack Oncology; Personal Genome Diagnostics; Thrive, An Exact Sciences Company
Consulting or Advisory Role - Cage Pharma; NeoPhore; Thrive Earlier Detection Corp
 
Kenneth W. Kinzler
Leadership - Haystack Oncology; Thrive Earlier Detection Corp
Stock and Other Ownership Interests - CAGE Pharma; Exact Sciences/Thrive Earlier Detection; Haystack Oncology; ManaT Bio; Neophore; Personal Genome Diagnostics
Consulting or Advisory Role - Cage Pharma; Exact Sciences/Thrive Earlier Detection; Haystack Oncology; ManaT Bio; Neophore; Personal Genome Diagnostics
Patents, Royalties, Other Intellectual Property - I receive royalties for intellectual property owned and managed by Johns Hopkins University.
 
Bert Vogelstein
Stock and Other Ownership Interests - Cage Pharma; Catalio; Haystack Oncology; NeoPhore; Personal Genome Diagnostics; Thrive Earlier Detection Corp
Consulting or Advisory Role - Cage Pharma; Catalio; Eisai; NeoPhore; Personal Genome Diagnostics; Sysmex
 
Jeanne Tie
Honoraria - Amgen; Merck Serono; MSD Oncology; Pierre Fabre; SERVIER; SERVIER
Consulting or Advisory Role - Bristol-Myers Squibb; Haystack Oncology; MSD Oncology; Novartis
Travel, Accommodations, Expenses - Roche
 
Peter Gibbs
Honoraria - Amgen; Merck; MSD Oncology; Roche; SERVIER
Consulting or Advisory Role - Haystack Oncology
Research Funding - Amgen (Inst); Bayer (Inst); Bristol-Myers Squibb/Sanofi (Inst); Merck Serono (Inst); Pierre Fabre (Inst); Roche (Inst); Roche Molecular Diagnostics (Inst); Servier (Inst)
Travel, Accommodations, Expenses - Servier